Stuart Senator Discusses Issues in Pharmaceuticals IP and Antitrust Litigation

Munger, Tolles & Olson attorney Stuart N. Senator participated in a panel discussion on pharmaceuticals intellectual property and antitrust litigation sponsored by the American Bar Association Section of Intellectual Property Law on June 9, 2015.

Mr. Senator and his fellow panelists discussed timely antitrust issues affecting the pharmaceuticals industry, including the application of the antitrust laws to life-cycle management or “product hopping,” Risk Evaluation and Mitigation Strategy (REMS), biosimilars, and “reverse payment” patent settlements.

Based in Munger Tolles’ Los Angeles office, Mr. Senator focuses his practice on antitrust litigation and attorney professional liability litigation. He is also General Counsel to the firm.